StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report released on Wednesday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 3.4 %

Shares of NASDAQ CHEK opened at $1.43 on Wednesday. Check-Cap has a 1-year low of $1.13 and a 1-year high of $3.94. The company has a market cap of $8.37 million, a PE ratio of -0.48 and a beta of 0.36. The company has a 50-day moving average of $1.68 and a two-hundred day moving average of $2.00.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.